Brokerages Set Tyra Biosciences, Inc. (NASDAQ:TYRA) Price Target at $30.83

Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA - Get Free Report) have been given a consensus rating of "Buy" by the six research firms that are presently covering the company, Marketbeat.com reports. Six research analysts have rated the stock with a buy rating. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $30.83.

Several analysts have commented on TYRA shares. Wedbush reaffirmed an "outperform" rating and set a $30.00 price objective on shares of Tyra Biosciences in a research note on Friday, March 28th. HC Wainwright reaffirmed a "buy" rating and set a $30.00 price target on shares of Tyra Biosciences in a report on Monday, March 31st. Finally, UBS Group started coverage on shares of Tyra Biosciences in a research report on Tuesday, January 7th. They issued a "buy" rating and a $28.00 price objective on the stock.

Tyra Biosciences Stock Performance

Shares of TYRA stock traded up $0.41 during mid-day trading on Thursday, hitting $9.47. 243,858 shares of the stock were exchanged, compared to its average volume of 248,970. Tyra Biosciences has a 12-month low of $6.42 and a 12-month high of $29.60. The stock has a market capitalization of $502.76 million, a price-to-earnings ratio of -5.88 and a beta of 1.19. The stock's fifty day simple moving average is $10.20 and its two-hundred day simple moving average is $14.49.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last released its quarterly earnings results on Thursday, March 27th. The company reported ($0.43) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.05. On average, research analysts expect that Tyra Biosciences will post -1.57 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Nina S. Kjellson sold 5,401 shares of the business's stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $13.76, for a total transaction of $74,317.76. Following the sale, the director now owns 443,885 shares of the company's stock, valued at approximately $6,107,857.60. The trade was a 1.20 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 15.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Tyra Biosciences

Several institutional investors have recently modified their holdings of the company. KLP Kapitalforvaltning AS acquired a new position in Tyra Biosciences during the fourth quarter worth $31,000. US Bancorp DE acquired a new position in shares of Tyra Biosciences during the 4th quarter worth $50,000. BNP Paribas Financial Markets purchased a new stake in shares of Tyra Biosciences in the 4th quarter worth about $60,000. Aquatic Capital Management LLC acquired a new stake in Tyra Biosciences in the 4th quarter valued at about $64,000. Finally, Exchange Traded Concepts LLC increased its holdings in Tyra Biosciences by 42.7% during the 1st quarter. Exchange Traded Concepts LLC now owns 11,861 shares of the company's stock valued at $110,000 after acquiring an additional 3,550 shares in the last quarter. Hedge funds and other institutional investors own 84.14% of the company's stock.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.